Using nanoparticles to deliver CRISPR technology to treat hepatitis E virus infections
Official title: Evaluation of nanoparticle delivered CRISPR/Cas13-targeting hepatitis E virus as a therapeutic
Funded at Ohio State University · NIH-11109731 · Data updated 2026-11-12
This study is exploring a new way to treat hepatitis E using tiny particles to deliver a special tool that can target and break down the virus, aiming to help patients, especially those with weakened immune systems, feel better and avoid serious health issues.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | June 6, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $236,250 |
| NIH project number | 5R21AI180487-02 |
| Project ID | NIH-11109731 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with hepatitis E virus infections, especially those who are immunocompromised due to conditions like HIV, cancer, or organ transplants.
✕Less likely to help
Patients who do not have hepatitis E virus infections or are not immunocompromised may not receive any benefit from this research.
What this research studies
This research investigates a novel approach to treat hepatitis E virus (HEV) infections using CRISPR/Cas13 technology delivered through nanoparticles. The goal is to specifically target and degrade the viral RNA, which could provide a more effective treatment option for patients, especially those who are immunocompromised. The study will focus on developing and testing these nanoparticles to ensure they can safely and effectively deliver the CRISPR components to the liver, where HEV primarily affects the body. By addressing the limitations of current treatments, this research aims to improve patient outcomes and reduce the risk of complications.
Why it matters
Potential benefit: If successful, this research could lead to a targeted and effective treatment for hepatitis E virus infections, particularly benefiting immunocompromised patients.
How similar studies have gone: While the use of CRISPR technology is relatively novel in treating viral infections, similar approaches have shown promise in other contexts, indicating potential for success in this area.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Kenney, Scott P — Ohio State University
- Study coordinator: Kenney, Scott P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.